ResMed builds on partnerships for growth

Updated on 14 June 2012

After a marginal drop in its revenue in 2010, ResMed picked up growth momentum in 2011 to reach $1.3 billion

ResMed builds on partnerships for growth

ResMed increased its R&D investments from $63.1 million in 2009 to $92 million in 2011

ResMed President & CEO Peter C FarrellDriving in the niche industry of sleep disorders, ResMed was aggressive in strengthening its portfolio through acquisitions and product expansion in the European region in 2011. ResMed took a smart approach of acquiring and partnering with small technology-focused companies that deepens its reach into the vastly under-penetrated market for sleep-disordered breathing.

ResMed acquired Germany-based Grundler, a developer of innovative medical humidification products. The company now has competitive humidification solutions that provide superior therapy under a broad range of operating conditions.

It also acquired Irish medical technology company, BiancaMed to get hands on wireless monitoring of disorders during sleep and breathing at home and in hospitals. Furthermore, ResMed formed a partnership with CareFusion to strengthen the market of its two recently launched product range, Stellar 100 and 150 in the US healthcare market.

ResMed also launched S9 bilevels and the S9 Adaptive Servo ventilator (ASV) for treating obstructive and central sleep apnea primarily in heart failure patients, and the Mirage FX mask in 2011.

After facing a marginal drop in its revenue in 2010 in comparison to 2009, ResMed again picked up growth momentum in 2011. The company registered a growth of 12.47 percent with revenue of $1.3 billion in 2011 against the previous year's revenue of $1.16 billion.

Previous 1

Leave a Reply

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X